Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Trodelvy“
Suchtreffer
Begriffe & Kennungen
Trodelvy
Eintrag öffnenTrodelvy · 4.1 Therapeutic indications · 1
Eintrag öffnenTrodelvy · 4.3 Contraindications · 1
Eintrag öffnenTrodelvy · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenTrodelvy · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenTrodelvy · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenTrodelvy · 4.5 · Based on the limited data available from patients who received UGT1A1 inhibitors (n=15) or inducers (n=7) whil
Eintrag öffnenTrodelvy · 4.5 · Concomitant administration of sacituzumab govitecan with inhibitors of UGT1A1 may increase the incidence of ad
Eintrag öffnenTrodelvy · 4.5 · Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Sacituzumab govit
Eintrag öffnenTrodelvy · 4.5 · No interaction studies have been performed.
Eintrag öffnenTrodelvy · 4.5 · UGT1A1 inducers
Eintrag öffnenTrodelvy · 4.5 · UGT1A1 inhibitors
Eintrag öffnenTrodelvy · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenTrodelvy · 4.8 Undesirable effects · 1
Eintrag öffnenTrodelvy · 4.8 · 10 System organ class Monotherapy In combination with pembrolizumab (SOC) and Frequency Renal and urinary diso
Eintrag öffnenTrodelvy · 4.8 · 11 10.6% in patients homozygous for the UGT1A1*28 allele, 6.4% in patients heterozygous for the UGT1A1*28 alle
Eintrag öffnenTrodelvy · 4.8 · 8 occur during treatment with these medicinal products in combination, even if these reactions were not report
Eintrag öffnenTrodelvy · 4.8 · 9 System organ class Monotherapy In combination with pembrolizumab (SOC) and Frequency Metabolism and nutritio
Eintrag öffnenTrodelvy · 4.8 · Adverse reactions are listed by System Organ Class and frequency category. Frequency categories are defined as
Eintrag öffnenTrodelvy · 4.8 · Adverse reactions observed in clinical studies of sacituzumab govitecan as monotherapy or in combination with
Eintrag öffnen